X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
exoVACC is modular vaccine system that utilizes the unique properties of exosomes to deliver antigens and adjuvants simultaneously and selectively to the same antigen presenting cells (APCs), driving an integrated innate, cellular and/or antibody-mediated immune response.
Lead Product(s): exoVACC
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
Codiak’s exoASO-STAT6 is an engineered exosome investigational therapeutic candidate designed to selectively deliver antisense oligonucleotides (ASOs) to disrupt STAT6 signaling in tumor associated macrophages (TAMs) and induce an anti-tumor immune response.
Lead Product(s): exoASO-STAT6
Therapeutic Area: Oncology Product Name: exoASO-STAT6
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
exoSTING (CDK-002) and exoIL-12 demonstrated favorable safety and tolerability profile at repeat doses tested and antitumor activity was observed in both injected and uninjected/distal lesions.
Lead Product(s): CDK-002
Therapeutic Area: Oncology Product Name: exoSTING
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2022
Details:
Codiak’s proprietary exoASO-STAT6 designed to enable the development of engineered exosome therapeutics for a wide spectrum of diseases and to manufacture them reproducibly and at scale to pharmaceutical standards.
Lead Product(s): exoASO-STAT6
Therapeutic Area: Oncology Product Name: exoASO-STAT6
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2022
Details:
Codiak’s proprietary engEx Platform is designed to enable the development of engineered exosome therapeutics for a wide spectrum of diseases and to manufacture them reproducibly and at scale to pharmaceutical standards.
Lead Product(s): engEx-AAV
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
Data demonstrated potential for exosome-based vaccine derived from exoVACC platform induce cross-neutralizing antibody protection against strains of coronavirus and antigen-specific and comprehensive immune response against structurally conserved region of coronavirus variant.
Lead Product(s): exoVACC
Therapeutic Area: Infections and Infectious Diseases Product Name: exoVACC
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2022
Details:
exoASO-STAT6 is an engineered exosome therapeutic candidate which selectively delivers antisense oligonucleotides to down-modulate STAT6 mRNA expression in TAMs. Precise targeting of STAT6 promotes the switch of TAMs to an M1, T cell attractive, anti-tumor phenotype.
Lead Product(s): exoASO-STAT6
Therapeutic Area: Oncology Product Name: exoASO-STAT6
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2022
Details:
exoSTING (CDK-002) is candidate engineered to incorporate a proprietary STING agonist inside the lumen of the exosome while expressing the exosomal protein, PTGFRN, on the exosome surface to facilitate specific uptake in tumor-resident antigen presenting cells.
Lead Product(s): CDK-002
Therapeutic Area: Oncology Product Name: exoSTING
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2021
Details:
Codiak has two programs in clinical development and expects to file an IND for exoASO-STAT6 – a novel exosome therapeutic carrying an antisense oligonucleotide (ASO) to target the transcription factor, STAT6 – by the end of the year.
Lead Product(s): exoASO-STAT6
Therapeutic Area: Oncology Product Name: exoASO-STAT6
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2021
Details:
ExoSTING is a novel engineered exosome therapeutic candidate currently being investigated in a Phase 1/2 clinical trial as a single agent for the treatment of multiple solid tumors.
Lead Product(s): CDK-002
Therapeutic Area: Oncology Product Name: exoSTING
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
